Search research articles
Contact Us
Filters
Showing results (21-30 of 69) with videos related to
Page
of 7
Sort By:
Blood
|
February 28, 2002
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
Wolf-K Hofmann, Letetia C Jones, Nathan A Lemp, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
April 13, 2005
FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells
Carmen Urbich, Andrea Knau, Stephan Fichtlscherer, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2020
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen
Patricia A Young, Daria Gaut, Davis K Kimaiyo, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B
|
February 27, 2003
Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV
Sven de Vos, Utz Krug, Wolf-Karsten Hofmann, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
February 21, 2003
Gene expression profile of serial samples of transformed B-cell lymphomas
Sven de Vos, Wolf-Karsten Hofmann, Thomas M Grogan, et al.
Experimental Hematology & Oncology
|
February 19, 2021
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Patrick B Johnston, Amanda F Cashen, Petros G Nikolinakos, et al.
Leukemia & Lymphoma
|
April 15, 2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
Wyndham H Wilson, Tycel Phillips, Leslie Popplewell, et al.
Nature Reviews. Clinical Oncology
|
December 30, 2016
The landscape of new drugs in lymphoma
Anas Younes, Stephen Ansell, Nathan Fowler, et al.
Journal of Hematology & Oncology
|
June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Sven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma
Sven de Vos, André Goy, Shaker R Dakhil, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 69) with videos related to
Sort By:
Page
of 7
Blood
|
February 28, 2002
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
Wolf-K Hofmann, Letetia C Jones, Nathan A Lemp, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
April 13, 2005
FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells
Carmen Urbich, Andrea Knau, Stephan Fichtlscherer, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2020
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen
Patricia A Young, Daria Gaut, Davis K Kimaiyo, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B
|
February 27, 2003
Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV
Sven de Vos, Utz Krug, Wolf-Karsten Hofmann, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
February 21, 2003
Gene expression profile of serial samples of transformed B-cell lymphomas
Sven de Vos, Wolf-Karsten Hofmann, Thomas M Grogan, et al.
Experimental Hematology & Oncology
|
February 19, 2021
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Patrick B Johnston, Amanda F Cashen, Petros G Nikolinakos, et al.
Leukemia & Lymphoma
|
April 15, 2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
Wyndham H Wilson, Tycel Phillips, Leslie Popplewell, et al.
Nature Reviews. Clinical Oncology
|
December 30, 2016
The landscape of new drugs in lymphoma
Anas Younes, Stephen Ansell, Nathan Fowler, et al.
Journal of Hematology & Oncology
|
June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Sven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma
Sven de Vos, André Goy, Shaker R Dakhil, et al.
Page
of 7